vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v18i4.2042vsp-2200Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWСаркома Юинга: молекулярно-генетические механизмы патогенезаSechenov First Moscow State Medical University (Sechenov University)https://orcid.org/0000-0002-4564-8439СамбуроваН. В.SamburovaNatalia V.

Самбурова Наталья Викторовна - кандидат медицинских наук, доцент кафедры патофизиологии/

119992, Москва, ул. Трубецкая, д. 8

nsamburova@bk.ruhttps://orcid.org/0000-0003-1707-2409ПименовИ. А.PimenovIgor A.https://orcid.org/0000-0003-4295-7436ЖевакТ. Н.ZhevakTatiana N.https://orcid.org/0000-0003-0151-9114ЛитвицкийП. Ф.LitvitskyPeter F.Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation201926112019184257263Copyright © Самбурова Н.В., Пименов И.А., Жевак Т.Н., Литвицкий П.Ф., 20192019Самбурова Н.В., Пименов И.А., Жевак Т.Н., Литвицкий П.Ф.Samburova N.V., Pimenov I.A., Zhevak T.N., Litvitsky P.F.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2200

Статья посвящена одной из наиболее распространенных у детей опухоли костной ткани — саркоме Юинга. Анализируются эпидемиологические данные, наиболее частые зоны поражения костей, клинические признаки, методы диагностики и терапии. Основное внимание уделено молекулярно-генетическим механизмам инициации канцерогенеза.

This article is devoted to the most common bone tissue tumor among children — Ewing's sarcoma. The epidemiological data, most frequent afflicted zones of bones, clinical signs, diagnostics and treatment methods are analysed. The main focus is on the molecular genetic mechanisms of carcinogenesis initiation.

опухоли костной тканисаркома Юингараспространенностьдиагностикатерапияканцерогенезмолекулярно-генетические механизмыbone tissue tumorsEwing’s sarcomaincidencediagnosticstreatmentcarcinogenesismolecular genetic mechanismsReferencesРыков М.Ю., Сусулёва Н.А., Чумакова О.В., и др. Онкологическая заболеваемость детского населения Российской Федерации и его обеспеченность медицинской помощью (врачами, коечным фондом, диагностическими и лечебными технологиями): анализ статистических данных за 2013 г. // Вопросы современной педиатрии. — 2015. — Т. 14. — № 6. — С. 686-691. doi: 10.15690/vsp.v14i6.1477.Rykov MYu, Susulyova NA, Chumakova OV, et al. Cancer incidence of child population of the russian federation and its provision of medical care (doctors, bedspace, diagnostic and therapeutic technologies): analysis of statistical data for 2013. Current Pediatrics. 2015;14(6):686-691. (In Russ). doi: 10.15690/vsp.v14i6.1477.Билялутдинова Д.И., Коваленко С.Г., Спичак И.И. Клинический случай опухоли семейства саркомы Юинга (примитивной нейроэктодермальной опухоли) редкой локализации в теменной кости // Педиатрический вестник Южного Урала. — 2015. — № 2. — С. 70-75.Bilyalutdinova DI, Kovalenko SG, Spichak II. Klinicheskiy sluchay opukholi semeystva sarkomy Yuinga (primi-tivnoy neyroektodermal'noy opukholi) redkoy lokalizatsii v temennoy kosti. Pediatricheskiy vestnik Yuzhnogo Urala. 2015;(2):70-75. (In Russ).von Heyking K, Roth L, Ertl M, et al. The posterior HOXD locus: its contribution to phenotype and malignancy of Ewing sarcoma. Oncotarget. 2016;7(27):41767-41780. doi: 10.18632/oncotar-get.9702.von Heyking K, Roth L, Ertl M, et al. The posterior HOXD locus: its contribution to phenotype and malignancy of Ewing sarcoma. Oncotarget. 2016;7(27):41767-41780. doi: 10.18632/oncotar-get.9702.Minas TZ, Surdez D, Javaheri T, et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. 2017;8(21):34141-34163. doi: 10.18632/oncotarget.9388.Minas TZ, Surdez D, Javaheri T, et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. 2017;8(21):34141-34163. doi: 10.18632/oncotarget.9388.Horbach L, Sinigaglia M, Da Silva CA, et al. Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. Mol Clin Oncol. 2018;8(6):719-724. doi: 10.3892/mco.2018.1608.Horbach L, Sinigaglia M, Da Silva CA, et al. Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. Mol Clin Oncol. 2018;8(6):719-724. doi: 10.3892/mco.2018.1608.Tanabe Y, Suehara Y, Kohsaka S, et al. IRE1a-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma. Oncotarget. 2018;9(18):14428-14443. doi: 10.18632/oncotarget.24467.Tanabe Y, Suehara Y, Kohsaka S, et al. IRE1a-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma. Oncotarget. 2018;9(18):14428-14443. doi: 10.18632/oncotarget.24467.Kovar H, Amatruda J, Brunet E, et al. The second European interdisciplinary Ewing sarcoma research summit — a joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016;7(8):8613-8624. doi: 10.18632/oncotarget.6937.Kovar H, Amatruda J, Brunet E, et al. The second European interdisciplinary Ewing sarcoma research summit — a joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016;7(8):8613-8624. doi: 10.18632/oncotarget.6937.Шалыга И.Ф., Ачинович С.Л., Козловская Т.В., и др. Саркома Юинга // Проблемы здоровья и экологии. — 2018. — № 1. — С. 101-105. [Shalyga IF, Achinovich SL, Kozlovskaya TV, et al. Ewing's sarcoma. Problems of health and ecology. 2018;(1): 101-105. (In Russ).]Shalyga IF, Achinovich SL, Kozlovskaya TV, et al. Ewing's sarcoma. Problems of health and ecology. 2018;(1): 101-105. (In Russ).Lacroix J, Kis Z, Josupeit R, et al. Preclinical testing of an oncolytic parvovirus in Ewing sarcoma: protoparvovirus H-1 induces apoptosis and lytic infection in vitro but fails to improve survival in vivo. Viruses. 2018;10(6):302. doi: 10.3390/v10060302.Lacroix J, Kis Z, Josupeit R, et al. Preclinical testing of an oncolytic parvovirus in Ewing sarcoma: protoparvovirus H-1 induces apoptosis and lytic infection in vitro but fails to improve survival in vivo. Viruses. 2018;10(6):302. doi: 10.3390/v10060302.Hoang NT, Acevedo LA, Mann MJ, Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018;10:1089-1114. doi: 10.2147/CMAR.S159641.Hoang NT, Acevedo LA, Mann MJ, Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018;10:1089-1114. doi: 10.2147/CMAR.S159641.Lin JK, Liang J. Sinonasal Ewing sarcoma: a case report and literature review. Perm J. 2018;22:17-086. doi: 10.7812/TPP/17-086.Lin JK, Liang J. Sinonasal Ewing sarcoma: a case report and literature review. Perm J. 2018;22:17-086. doi: 10.7812/TPP/17-086.Becker RG, Gregianin LJ, Galia CR, et al. What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group EWING1. BMC Cancer. 2017;17(1):420. doi: 10.1186/s12885-017-3391-5.Becker RG, Gregianin LJ, Galia CR, et al. What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group EWING1. BMC Cancer. 2017;17(1):420. doi: 10.1186/s12885-017-3391-5.Negru ME, Sponghini AP Rondonotti D, et al. Primary Ewing's sarcoma of the sinonasal tract, eroding the ethmoid and sphenoid sinus with intracranial extension: a rare case report. Mol Clin Oncol. 2015;3(4):807-810. doi: 10.3892/mco.2015.548.Negru ME, Sponghini AP Rondonotti D, et al. Primary Ewing's sarcoma of the sinonasal tract, eroding the ethmoid and sphenoid sinus with intracranial extension: a rare case report. Mol Clin Oncol. 2015;3(4):807-810. doi: 10.3892/mco.2015.548.Karski EE, Mcllvaine E, Segal MR, et al. Identification of discrete prognostic groups in Ewing sarcoma. Pediatr Blood Cancer. 2016;63(1):47-53. doi: 10.1002/pbc.25709.Karski EE, Mcllvaine E, Segal MR, et al. Identification of discrete prognostic groups in Ewing sarcoma. Pediatr Blood Cancer. 2016;63(1):47-53. doi: 10.1002/pbc.25709.Monument MJ, Johnson KM, McIlvaine E, et al. Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One. 2014;9(8):e104378. doi: 10.1371/journal.pone.0104378.Monument MJ, Johnson KM, McIlvaine E, et al. Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One. 2014;9(8):e104378. doi: 10.1371/journal.pone.0104378.Семенова А.И. Саркома Юинга и периферические примитивные нейроэктодермальные опухоли (клиника, диагностика, лечение) // Практическая онкология. — 2005. — Т. 6. — № 4. — С. 234-239.Semenova AI. Ewing's sarcoma and peripheral primitive neuroectodermal tumors (clinic, diagnosis, treatment). Practical Oncology. 2005;6(4):234-239. (In Russ).Allegretti M, Casini B, Mandoj C, et al. Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts. Ther Adv Med Oncol. 2018;10:1758835918774337. doi: 10.1177/1758835918774337.Allegretti M, Casini B, Mandoj C, et al. Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts. Ther Adv Med Oncol. 2018;10:1758835918774337. doi: 10.1177/1758835918774337.Sand LG, Szuhai K, Hogendoorn PC. Sequencing overview of Ewing sarcoma: a journey across genomic, epigenomic and tran-scriptomic landscapes. Int J Mol Sci. 2015;16(7):16176-16215. doi: 10.3390/ijms160716176.Sand LG, Szuhai K, Hogendoorn PC. Sequencing overview of Ewing sarcoma: a journey across genomic, epigenomic and tran-scriptomic landscapes. Int J Mol Sci. 2015;16(7):16176-16215. doi: 10.3390/ijms160716176.Beck R, Monument MJ, Watkins WS, et al. EWS/FLI-res-ponsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genet. 2012; 205(6):304-312. doi: 10.1016/j.cancergen.2012.04.004.Beck R, Monument MJ, Watkins WS, et al. EWS/FLI-res-ponsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genet. 2012; 205(6):304-312. doi: 10.1016/j.cancergen.2012.04.004.Cash T, Mcllvaine E, Krailo MD, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2016;63(10):1771-1779. doi: 10.1002/pbc.26096.Cash T, Mcllvaine E, Krailo MD, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2016;63(10):1771-1779. doi: 10.1002/pbc.26096.Kawano H, Nitta N, Ishida M, et al. Primary pericranial Ewing's sarcoma on the temporal bone: a case report. Surg Neurol Int. 2016;7(Suppl 15):S444-S448. doi: 10.4103/2152-7806.183545.Kawano H, Nitta N, Ishida M, et al. Primary pericranial Ewing's sarcoma on the temporal bone: a case report. Surg Neurol Int. 2016;7(Suppl 15):S444-S448. doi: 10.4103/2152-7806.183545.Galyfos G, Karantzikos GA, Kavouras N, et al. Extraosseous Ewing sarcoma: diagnosis, prognosis and optimal management. Indian J Surg. 2016;78(1):49-53. doi: 10.1007/s12262-015-1399-0.Galyfos G, Karantzikos GA, Kavouras N, et al. Extraosseous Ewing sarcoma: diagnosis, prognosis and optimal management. Indian J Surg. 2016;78(1):49-53. doi: 10.1007/s12262-015-1399-0.Hockertz T, Velickovic M. Successful spontaneous pregnancy after treatment for Ewing sarcoma including sacrectomy. Case Rep Obstet Gynecol. 2018;2018:2484036. doi: 10.1155/2018/2484036.Hockertz T, Velickovic M. Successful spontaneous pregnancy after treatment for Ewing sarcoma including sacrectomy. Case Rep Obstet Gynecol. 2018;2018:2484036. doi: 10.1155/2018/2484036.Samburova NV, Kalinin SA, Zhevak TN, Litvitsky PF. Chondroblastoma: etiology, pathogenesis, methods of diagnosis and treatment. Oncopediatrics. 2018;5(4):248-256. (In Russ.) doi: 10.15690/onco.v5i4.1968.Samburova NV, Kalinin SA, Zhevak TN, Litvitsky PF. Chondroblastoma: etiology, pathogenesis, methods of diagnosis and treatment. Oncopediatrics. 2018;5(4):248-256. (In Russ.) doi: 10.15690/onco.v5i4.1968.Травкина Ю.В., Жевак Т.Н., Литвицкий П.Ф. Хордома: этиология, патогенез, методы диагностики и лечения // Вопросы современной педиатрии. — 2018. — Т. 17. — № 4. — С. 266-271. doi: 10.15690/vsp.v17i4.1917.Travkina JV, Zhevak TN, Litvitsky PF. Chordoma: etiology, pathogenesis, diagnosis, treatment. Current pediatrics. 2018;17(4):266-271. (In Russ). doi: 10.15690/vsp.v17i4.1917.Pedersen EA, Menon R, Bailey KM, et al. Activation of Wnt/p-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 2016;76(17):5040-5053. doi: 10.1158/0008-5472.CAN-15-3422.Pedersen EA, Menon R, Bailey KM, et al. Activation of Wnt/p-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 2016;76(17):5040-5053. doi: 10.1158/0008-5472.CAN-15-3422.Kim SK, Park YK. Ewing sarcoma: a chronicle of molecular pathogenesis. Hum Pathol. 2016;55:91-100. doi: 10.1016/j.hum-path.2016.05.008.Kim SK, Park YK. Ewing sarcoma: a chronicle of molecular pathogenesis. Hum Pathol. 2016;55:91-100. doi: 10.1016/j.hum-path.2016.05.008.Joseph SA, Bhandari R, Albert A, et al. Saving the hand: Role of multimodality therapy for Ewing's sarcoma family tumor of the palm. Adv Radiat Oncol. 2018;3(2):205-208. doi: 10.1016/j.adro.2018.01.005.Joseph SA, Bhandari R, Albert A, et al. Saving the hand: Role of multimodality therapy for Ewing's sarcoma family tumor of the palm. Adv Radiat Oncol. 2018;3(2):205-208. doi: 10.1016/j.adro.2018.01.005.Lawlor ER, Sorensen PH. Twenty years on: what do we really know about Ewing sarcoma and what is the path forward? Crit Rev Oncog. 2015;20(3-4):155-171. doi: 10.1615/critrevon-cog.2015013553.Lawlor ER, Sorensen PH. Twenty years on: what do we really know about Ewing sarcoma and what is the path forward? Crit Rev Oncog. 2015;20(3-4):155-171. doi: 10.1615/critrevon-cog.2015013553.Passacantilli I, Frisone P De Paola E, et al. hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/ AKT/mTOR pathway in Ewing sarcoma cells. Nucleic Acids Res. 2017;45(21):12270-12284. doi: 10.1093/nar/gkx831.Passacantilli I, Frisone P De Paola E, et al. hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/ AKT/mTOR pathway in Ewing sarcoma cells. Nucleic Acids Res. 2017;45(21):12270-12284. doi: 10.1093/nar/gkx831.Li T, Zhang F, Cao Y, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the ileum: case report of a 16-year-old Chinese female and literature review. Diagn Pathol. 2017;12(1):37. doi: 10.1186/s13000-017-0626-3.Li T, Zhang F, Cao Y, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the ileum: case report of a 16-year-old Chinese female and literature review. Diagn Pathol. 2017;12(1):37. doi: 10.1186/s13000-017-0626-3.Lerman DM, Monument MJ, Mcllvaine E, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62(5): 759-765. doi: 10.1002/pbc.25340.Lerman DM, Monument MJ, Mcllvaine E, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62(5): 759-765. doi: 10.1002/pbc.25340.Yuan B, Ji W, Xia H, Li J. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. Mol Med Rep. 2018;17(3): 4291-4298. doi: 10.3892/mmr.2018.8418.Yuan B, Ji W, Xia H, Li J. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. Mol Med Rep. 2018;17(3): 4291-4298. doi: 10.3892/mmr.2018.8418.Loganathan SN, Tang N, Fleming JT, et al. BET bromodo-main inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget. 2016;7(28):43504-43517. doi: 10.18632/oncotarget.9762.Loganathan SN, Tang N, Fleming JT, et al. BET bromodo-main inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget. 2016;7(28):43504-43517. doi: 10.18632/oncotarget.9762.Katschnig AM, Kauer MO, Schwentner R, et al. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cyto-skeletal autoregulatory feedback in Ewing sarcoma. Oncogene. 2017;36(43):5995-6005. doi: 10.1038/onc.2017.202.Katschnig AM, Kauer MO, Schwentner R, et al. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cyto-skeletal autoregulatory feedback in Ewing sarcoma. Oncogene. 2017;36(43):5995-6005. doi: 10.1038/onc.2017.202.Johnson KM, Taslim C, Saund RS, Lessnick SL. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. PLoS One. 2017; 12(11):e0186275. doi: 10.1371/journal.pone.0186275.Johnson KM, Taslim C, Saund RS, Lessnick SL. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. PLoS One. 2017; 12(11):e0186275. doi: 10.1371/journal.pone.0186275.Son J, Shen SS, Margueron R, Reinberg D. Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin. Genes Dev. 2013;27(24):2663-2677. doi: 10.1101/gad.225888.113.Son J, Shen SS, Margueron R, Reinberg D. Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin. Genes Dev. 2013;27(24):2663-2677. doi: 10.1101/gad.225888.113.Liu J, Cao L, Chen J, et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature. 2009; 459(7245):387-392. doi: 10.1038/nature08040.Liu J, Cao L, Chen J, et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature. 2009; 459(7245):387-392. doi: 10.1038/nature08040.Katschnig AM, Kauer MO, Schwentner R, et al. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cyto-skeletal autoregulatory feedback in Ewing sarcoma. Oncogene. 2017;36(43):5995-6005. doi: 10.1038/onc.2017.202.Katschnig AM, Kauer MO, Schwentner R, et al. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cyto-skeletal autoregulatory feedback in Ewing sarcoma. Oncogene. 2017;36(43):5995-6005. doi: 10.1038/onc.2017.202.von Heyking K, Calzada-Wack J, Gollner S, et al. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma. Mol Oncol. 2017;11(9):1288-1301. doi: 10.1002/1878-0261.12057.von Heyking K, Calzada-Wack J, Gollner S, et al. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma. Mol Oncol. 2017;11(9):1288-1301. doi: 10.1002/1878-0261.12057.Minami Y Matsumoto S, Ae K, et al. Successful complete response of tumor thrombus after combined with chemotherapy and irradiation for Ewing sarcoma. Case Rep Orthop. 2018;2018: 5238512. doi: 10.1155/2018/5238512.Minami Y Matsumoto S, Ae K, et al. Successful complete response of tumor thrombus after combined with chemotherapy and irradiation for Ewing sarcoma. Case Rep Orthop. 2018;2018: 5238512. doi: 10.1155/2018/5238512.Huh WW, Daw NC, Herzog CE, et al. Ewing sarcoma family of tumors in children younger than 10 years of age. Pediatr Blood Cancer. 2017;64(4). doi: 10.1002/pbc.26275.Huh WW, Daw NC, Herzog CE, et al. Ewing sarcoma family of tumors in children younger than 10 years of age. Pediatr Blood Cancer. 2017;64(4). doi: 10.1002/pbc.26275.Феденко А.А., Бохян А.Ю., Горбунова В.А., и др. Практические рекомендации по лекарственному лечению первичных злокачественных опухолей костей (остеосаркомы, саркомы Юинга) // Злокачественные опухоли. — 2017. — Т. 7. — № 3-S2. — С. 203-215. doi: 10.18027/2224-5057-2017-7-3s2-203-215.Fedenko AA, Bohyan AYu, Gorbunova VA et al. Practical recommendations for the treatment of primary malignant bone tumors (osteosarcomas, Ewing's sarcoma). Malignant tumors. 2017;7(3-S2):203-215. (In Russ). doi: 10.18027/2224-5057-2017-7-3s2-203-215.Jacobs AJ, Fishbein J, Levy CF, et al. Chest wall Ewing sarcoma: a population-based analysis. J Surg Res. 2016;204(2):475-480. doi: 10.1016/j.jss.2016.05.033.Jacobs AJ, Fishbein J, Levy CF, et al. Chest wall Ewing sarcoma: a population-based analysis. J Surg Res. 2016;204(2):475-480. doi: 10.1016/j.jss.2016.05.033.Pilbeam K, Wang H, Taras E, et al. Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. Oncotarget. 2017;9(15): 11938-11947. doi: 10.18632/oncotarget.21187.Pilbeam K, Wang H, Taras E, et al. Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. Oncotarget. 2017;9(15): 11938-11947. doi: 10.18632/oncotarget.21187.Subbiah V, Anderson P Targeted therapy of Ewing's sarcoma. Sarcoma. 2011;2011:686985. doi: 10.1155/2011/686985.Subbiah V, Anderson P Targeted therapy of Ewing's sarcoma. Sarcoma. 2011;2011:686985. doi: 10.1155/2011/686985.

The authors declare that there are no conflicts of interest present.